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Summary: In a retrospective case series study, medical records were evaluated for all male 
patients infected with human immunodeficiency virus (HIV) diagnosed over a one-year period 
with foot fractures (n = 30) confirmed by magnetic resonance imaging at a Los Angeles 
outpatient private practice rheumatology clinic. Proportionally more patients had received 
tenofovir   prefracture (17 [57%]) than those who had not (13 [43%]). At fracture diagnosis, 
these two groups were similar in median age (49 versus 48 years), HIV-1 RNA (both 1.7 log10 
copies/mL), CD4 count (300 versus 364/mm3), time between HIV diagnosis and foot fracture 
(both 17 years), family history of degenerative bone disease (24% versus 23%), prevalence 
of malabsorption syndrome, renal failure, calcium deficiency, or vitamin D deficiency, and 
concurrent use of bisphosphonates, calcitonin, and diuretics. However, more tenofovir-treated 
patients had osteoporosis (35% versus 8%), stress-type fractures (53% versus 31%), concurrent 
fractures (12% versus 0%), wasting syndrome (29% versus 15%), truncal obesity (18% versus 
8%), smoked cigarettes (more than one pack/day for more than one year; 35% versus 8%), dual 
energy X-ray absorptiometry (DEXA) T scores , −2.4 (denoting osteoporosis) at the femur (24% 
versus 9%) and spine (47% versus 36%), and had received protease inhibitors (71%   versus 46%), 
non-nucleoside reverse transcriptase inhibitors (24% versus 0%), prednisone (24% versus 0%), 
testosterone (47% versus 23%), and teriparatide (29% versus 8%). Median time from tenofovir 
initiation until fracture was 2.57 (range 1.17–5.69) years. In conclusion, more foot fractures were 
observed in tenofovir-treated patients than in non-tenofovir-treated patients with HIV infection. 
Comorbidities and/or coadministered drugs may have been contributory.
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Introduction
Fractures among patients infected with human immunodeficiency virus (HIV) have 
been the focus of an increasing number of studies since 2000.1–17 Such fractures 
have been documented to occur more frequently than in people not infected by HIV6 
and to involve longer healing times and an increased risk of infection.18 The large 
US prospective cohort HIV Outpatient Study (n = 5826) reported that, in 2006, the 
  frequency of all fractures among HIV-infected patients aged 25–54 years was over 
two-fold higher than in the US general outpatient population (84.2 versus 35.6 fractures 
per 10,000 people, adjusted for gender).6 HIV-infected patients have been shown to be 
at particularly high risk for developing fractures if they are aged $47 years (compared 





hepatitis C coinfection, or are an intravenous drug user.6 
Because combination antiretroviral therapy has allowed 
more and more HIV-infected people to live well beyond 
50 years, when osteoblastic activity significantly declines,1 
the occurrence of fractures is expected to increase in this 
population in the future.
The higher prevalence of fractures among HIV-infected 
patients compared with the general population is due in 
part to their lower bone mineral density, which makes their 
bones more fragile and susceptible to breaking.1,4,6,13 This is 
reflected in their six-fold higher rate of osteopenia and nearly 
four-fold higher rate of osteoporosis.6 For every one standard 
deviation reduction in vertebral bone mineral density, there 
is a two-fold increased risk of vertebral fracture.1 HIV itself 
appears to lower bone mineral density due to the presence 
of increased levels of certain proinflammatory cytokines 
(interleukin-1, interleukin-6, and tumor necrosis factor) that 
directly accelerate bone loss.13
Many antiretroviral and nonantiretroviral drugs are also 
known to contribute to low bone mineral density through 
a variety of mechanisms, including enhanced osteoclastic 
activity, reduction in osteoblastic activity, impaired cal-
cium absorption, and renal phosphate wasting.8,13 Of the 
reverse transcriptase inhibitors, the nucleotide, tenofovir 
disoproxil fumarate, has been most documented to produce 
significant reductions in bone mineral density following 
initiation of therapy.10,19–25 In clinical trials that have directly 
compared tenofovir with the nucleoside reverse transcriptase 
inhibitors, ie, stavudine, zidovudine, and abacavir, tenofovir 
was found to reduce bone mineral density to a greater 
degree.22,26,27 In a cross-sectional observational study by 
Guillemi et al10 in 285 unselected adult HIV patients (80% 
Caucasian, 85% male, median age 48 years), multivariate 
analysis revealed that tenofovir exposure for at least three 
months and lower body mass index, but not exposure to other 
nucleosides or protease inhibitors, were risk factors for low 
bone mineral density.
To date, studies of fractures in HIV-infected patients 
have focused primarily on fractures of the hip and spine, as 
confirmed by dual energy X-ray absorptiometry (DEXA) or 
magnetic resonance imaging.4,14,18,21,28 Fractures of the feet 
have rarely been mentioned in any publication.   Considering 
their weight-bearing role, feet would be expected to be highly 
vulnerable to fracture in HIV patients, especially those 
with reduced bone mineral density and the common HIV-
associated peripheral neuropathy. The purpose of the present 
study was to describe the clinical, laboratory, and medical 
history characteristics of all male HIV-infected patients 
diagnosed with foot fractures within a one-year period at a 
private practice rheumatology clinic in Los Angeles, and to 
differentiate these characteristics in tenofovir-treated versus 
non-tenofovir-treated patients.
Materials and methods
In this retrospective case series study (COL109415), a rheu-
matologist (AAH) and podiatrist (RJJ) reviewed the medical 
records for all male HIV-infected patients in Los Angeles area 
outpatient podiatry and rheumatology clinics who had been 
diagnosed as having foot fractures confirmed by magnetic 
resonance imaging (n = 30) over a one-year period (2006–
2007). In most cases, the patients had been seen initially in 
private podiatry clinics in Los Angeles and were referred to 
the Center for Rheumatology. However, some patients were 
seen first at the Center for Rheumatology and were then 
referred to RJJ’s private podiatry practice for foot fracture 
assessment. Female fracture patients were excluded from the 
study because it was felt that their greater fracture risk due to 
lower bone mineral density and bone mass,29 and the compli-
cation of premenopausal and postmenopausal estrogen use 
(oral contraceptives and estrogen supplements,30 respectively) 
could lead to data that would not be comparable with that 
from a solely male population. Fracture data were included 
for analysis only for patients whose fractures had occurred 
either in the absence of trauma or after only trivial trauma. 
Medical records for patients with fractures due to high-
energy traumatic injury (eg, a motor vehicle accident) were 
excluded from analysis. Excel® sheets were used to capture 
data pertaining to the patients’ demographics, HIV history, 
comorbidities, alcohol intake, smoking history, highly active 
antiretroviral therapy (HAART)/non-HIV drug prescription 
history, bone mineral density scores by DEXA, fracture type, 
and laboratory values (especially serum calcium, phospho-
rus, alkaline phosphatase, thyroid-stimulating hormone, 
25-hydroxyvitamin D, and parathyroid hormone).
The investigators also noted the characteristics of the foot 
fracture events, which included the situation surrounding the 
fracture, location/type of fracture, the presence of concur-
rent fractures in other body regions, the time between HIV 
  diagnosis and foot fracture occurrence, the time between 
the start of a particular treatment and foot fracture, and how 
fractures were managed. Statistical analysis was   primarily 
descriptive, although stepwise logistic regression   analyses 
were performed to evaluate a correlation between the 
  category variables, ie, femur DEXA T scores ,−1.5 or $−1.5 HIV/AIDS - Research and Palliative Care 2011:3









Age, years; median (range) 49 (40–63) 48 (44–80)
Caucasian: Black ratio 13 (76%):2 (18%) 12 (100%):0
Weight, kg; median (range) 80 (61–116) 72 (57–103)
HIV-1 RNA, log10 copies/mL; 
  Median (range) 1.7 (1.7–4.7) 1.7 (1.7–4.6)
  ,50, n (%) 14 (82%) 8 (73%)
  $50, n (%) 3 (18%) 3 (27%)
CD4 cell count, cells/mm3; 
  Median (range) 300 (150–700) 364 (100–650)
  ,200, n (%) 1 (6%) 3 (27%)
  $200, n (%) 16 (94%) 8 (73%)
Type of fracture
  Stress fracture 9 (53%) 4 (31%)
Laboratory values (mean)
  Alkaline phosphatase (IU/L) 103.5 72.0
  Calcium (mg/dL) 9.5 9.4
  WBC (thousand cells/mm3) 5.5 6.3
  Parathyroid hormone (pg/mL) 40.8 32.0
  25-Hydroxyvitamin D (ng/mL) 36.8 26.0
Comorbidities
  Osteoporosis 7 (41%) 3 (23%)
  Smoker (chronic, .1  
  pack/day)
6 (35%) 1 (8%)
  Wasting syndrome 5 (29%) 2 (15%)
  Alcoholism 2 (12%) 4 (31%)
  Concurrent fractures 2 (12%) 0
  Anemia due to chronic  
  disease
0 3 (23%)
  Truncal obesity 3 (18%) 1 (8%)
Concurrent drugs
  Protease inhibitor* 12 (71%) 6 (46%)
  NNRTI† 6 (35%) 2 (15%)
  Prednisone 4 (24%) 0
  Calcium supplements 17 (100%) 11 (85%)
  Vitamin D supplements 17 (100%) 11 (85%)
  Testosterone 8 (47%) 3 (23%)
  Teriparatide 5 (29%) 1 (8%)
DeXA scan category*,‡
  Femur T score
   −2.4 to −1.5 (osteopenia) 7 (41%) 4 (36%)
   −2.4 (osteoporosis) 4 (24%) 1 (9%)
  Spine T score
   −2.4 to −1.5 (osteopenia) 6 (35%) 4 (36%)
   ,−2.4 (osteoporosis) 8 (47%) 4 (36%)
Notes:  *In  the  TDF  and  non-TDF  groups,  protease  inhibitors  were  lopinavir/
ritonavir (9 versus 3), ritonavir (4 versus 1), atazanavir (3 versus 0), fosamprenavir 
(1 versus 1), darunavir (0 versus 1), and indinavir (0 versus 1);  †NNRTIs were 
nevirapine  (3  versus  2)  and  efavirenz  (3  versus  0);  ‡Logistic  regression  analysis 
showed a relationship between femur DeXA T scores ,−1.5 and body weight 
(P = 0.036) and serum glucose (P = 0.034). No relationship was seen between femur 
or spine DeXA T scores ,−1.5 or ,−2.4 and alendronate or testosterone use, 
serum creatinine, blood urea nitrogen, electrolytes, or 25-hydroxyvitamin D. 
Abbreviations:  TDF,  tenofovir;  DeXA,  dual  energy  X-ray  absorptiometry;   
NNRTI, non-nucleoside reverse transcriptase inhibitors; WBC, white blood cells; 
HAART, highly active antiretroviral therapy.
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or spine DEXA T scores ,−1.5 or $−1.5, and independent 
variables (baseline demographic characteristics, HIV-1 RNA, 
CD4 cell count, laboratory values, comorbidities, and concur-
rently administered drugs).
Results
Foot fractures primarily affected the metatarsal areas. These 
fractures were marked by pain, often of the pinpoint type 
when the fracture area was touched, with concomitant 
  swelling and little or no bruising. Proportionally more 
patients with foot fractures had received tenofovir-containing 
antiretroviral (17 [57%]) than non-tenofovir-containing 
antiretroviral (13 [43%]) drugs prior to the fracture. Median 
time from tenofovir initiation until fracture was 2.57 
(range 1.17–5.69) years. At the time fracture was diagnosed, 
the tenofovir and non-tenofovir groups did not differ signifi-
cantly in median or mean age (49 versus 48 years and 50.0 
versus 54.2 years, respectively). Although there were outliers 
in age in each of these groups, ie, a 63-year-old in the tenofo-
vir group and an 80-year-old in the non-tenofovir group, most 
of the patients were in their mid to late forties. The tenofovir 
and non-tenofovir groups were also similar with respect to 
baseline viral load (2.1 versus 2.4 log10 copies/mL), time 
between HIV diagnosis and foot fracture (both 17.0 years), 
proportion of fractures affecting the metatarsophalangeal area 
(12% versus 15%), incidence of concurrent vertebral frac-
ture (12% versus 15% of all foot fracture cases), and family 
history of osteoporosis (24% versus 23% of cases, Table 1). 
No between-group   differences were observed regarding 
presence of most comorbidities, including hypogonadism, 
hypertension, malabsorption syndrome, renal failure, calcium 
deficiency, or vitamin D deficiency, nor were differences seen 
in serum laboratory values for calcium, albumin, potassium, 
blood urea nitrogen, sodium, creatinine, chloride, glucose, 
liver enzymes, and hematocrit.
More patients in the tenofovir group than in the non-
  tenofovir group were osteoporotic, smoked cigarettes 
  regularly, and had truncal obesity and wasting syndrome. 
Fewer tenofovir-treated patients had a history of alcoholism 
and anemia secondary to chronic disease. The tenofovir 
group had higher median plasma concentrations of   alkaline 
  phosphatase (104 IU/L versus 72 IU/L), parathyroid hor-
mone (41 pg/mL versus 32 pg/mL), 25-hydroxyvitamin D 
(37 ng/mL versus 26 ng/mL), and a lower median white 
blood cell count (5.5 × 103/mm3 versus 6.3 × 103/mm3). 
Evaluation of prior nucleoside reverse transcriptase inhibitor, 





inhibitor use showed that more patients in the tenofovir group 
had taken lopinavir/ritonavir (53% versus 23%) and ritonavir 
(24% versus 8%), whereas more patients in the non-tenofovir 
group had taken abacavir/lamivudine (31% versus 6%). No 
between-group differences were observed in the frequency 
of use of any other individual antiretroviral agents.
Logistic regression analyses showed a significant 
relationship between femur DEXA T-scores ,−1.5 and 
decreased body weight (P = 0.036) and increased serum 
glucose (P = 0.03). No relationship was seen between femur 
or spine DEXA T scores ,−1.5 and alendronate use or 
  testosterone use, serum creatinine, serum blood urea nitrogen, 
electrolytes, or 25-hydroxyvitamin D levels.
The fractures were treated with immobilization of the 
foot, often with the aid of a casted stiff-soled shoe to be worn 
to prevent pressure or bending of the fracture area. Surgery 
was not required, and crutches were generally needed only 
for metatarsal base injuries. With these precautions, fractures 
usually required 4–6 weeks to heal fully. In   tenofovir-treated 
patients, tenofovir was generally retained in regimens. 
  Following healing, custom orthotics were created for the 
patients for insertion into shoes to reduce pressure on the 
  previously fractured foot areas. For patients whose bone 
  mineral density values demonstrated osteoporosis or 
osteopenia, treatment with supplemental calcium, vitamin D, 
bisphosphonates, or teriparatide was considered.
Discussion
This small pilot study suggests that foot fractures may occur 
more often in HIV-infected patients treated with tenofovir-
containing HAART than non-tenofovir-containing HAART. 
Concern about an association of tenofovir with fractures 
was initially raised by preclinical studies that showed a 
higher risk of spontaneous fractures and bone abnormalities 
in rhesus monkeys with simian   immunodeficiency 
virus infection administered supratherapeutic doses of 
tenofovir (30 mg/kg/day) subcutaneously for one week 
to 24 months (mean, 14 months) compared with no 
  treatment.31 These bone effects were associated with 
elevated alkaline   phosphatase levels and decreased serum 
phosphorus   levels. Histomorphometric assessment of the 
tibial diaphyses in tenofovir-treated monkeys revealed 
increased osteoid seam width, consistent with defective 
mineralization of new bone, despite reduction or reversal of 
tibial bone resorption. A   further preclinical study reported 
  completely unmineralized secondary osteons in the tibia of 
a 16-month-old rhesus monkey whose mother had received 
high doses of tenofovir while pregnant.32
Clinical trials evaluating tenofovir have also demonstrated 
the adverse effect of the drug on bone. In GS-99-903, 
a clinical registration trial that compared tenofovir/lamivu-
dine/efavirenz (n = 299) with stavudine/lamivudine/efavirenz 
(n = 303) in antiretroviral-naïve patients, tenofovir-treated 
patients experienced a significantly greater mean percentage 
decrease from baseline in lumbar spine bone mineral density 
at week 144 (−2.2% versus −1.0% stavudine, P = 0.001) and 
a trend for greater bone mineral density reduction at the hip 
(−2.8% versus −2.4% stavudine, P = 0.06).26
Two subsequent clinical trials similarly showed 
that tenofovir, whether combined with emtricitabine or 
  lamivudine, caused significantly greater bone mineral density 
reduction than comparator nucleoside reverse transcriptase 
inhibitor backbones.21,28 However, none of these clinical 
  trials reported a significantly higher frequency of fractures 
in tenofovir-treated patients despite the tenofovir-associated 
reduction in bone mineral density. This underscores clinical 
evidence demonstrating that reduced bone mineral density is 
just one contributor to fractures and that bone mineral density 
alone cannot serve as the only predictor of fracture. In fact, 
reduced bone mineral density alone generally imparts less 
than 25% increased risk of vertebral fractures.33 The effect 
of decreased bone mineral density on foot fracture risk has 
yet to be investigated.
Where fracture data have been reported previously in 
HIV-infected patients receiving HAART, these have dealt 
primarily with vertebral fractures rather than foot   fractures. 
In fact, in an assessment of patient medical records of 
approximately 8600 HIV-infected patients (78% male, 
70% Caucasian, median age 45 years, 46% smokers, 81% 
of the HAART regimens including one protease inhibitor 
and 22% including tenofovir) at nine US HIV clinics, 55% 
of 55 fractures observed were vertebral, only one of which 
occurred with a concurrent foot fracture.14 The other most 
frequent sites of fracture were the lower extremities (27%, 
which could have included foot fractures, although these 
were not specified), upper extremities (6%), and clavicle 
(4%). The regimens associated with these fractures were 
not delineated. As in our study, patients who had fractures 
generally remained on the antiretroviral treatment they had 
been receiving at the time fracture occurred, and remediation 
similarly consisted of immobilization of the fracture areas, 
with institution of calcium, vitamin D, and bisphosphonates 
if osteoporosis had been detected by bone mineral density 
measurements.
Foot fractures believed to be related to tenofovir were 
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37–62 years, 12–17 months after tenofovir was added to their 
HAART regimens.24,34,35 Their regimens also included either 
ritonavir-boosted atazanavir or lopinavir. In these cases, bone 
scintigraphy revealed concurrent fissure fractures in multiple 
body areas, especially the legs, ribs, pelvis, and femur. 
Laboratory work confirmed osteomalacia that was likely 
due to tenofovir-related proximal renal tubular dysfunction, 
which was marked by phosphaturia, proteinuria, glycosuria, 
and calciuria. Tenofovir was discontinued, remedial oral 
25-hydroxyvitamin D3, neutral sodium-potassium phosphate, 
and/or calcitriol treatment was initiated, and the condition 
of the patients resolved and laboratory values and renal 
function usually normalized within 12 weeks. Generalized 
fractures in 12 of 22 patients who had developed proximal 
renal tubular dysfunction secondary to tenofovir were also 
reported by Woodward et al.25 In these patients, phosphaturia 
led to hypophosphatemia, which in turn led to osteomalacia 
and fracture. In the tenofovir-treated patients in our study, 
osteomalacia could not be ruled out as a potential cause of, 
or prodromal condition for, foot fractures because we did not 
have serum phosphate data, or urinary phosphate, glucose, 
or protein data. Our tenofovir cohort did not present with 
a greater number of symptoms suggestive of generalized 
osteomalacia (diffuse body pain and muscle weakness) than 
did the non-tenofovir group. However, it did have more 
stress-type and concurrent fractures and higher parathyroid 
hormone and alkaline phosphatase levels, all of which are 
often associated with osteomalacia.36
Both the tenofovir and non-tenofovir groups in our study 
had several factors that could have influenced the occurrence 
of foot fractures. A larger proportion of tenofovir-treated 
patients took the protease inhibitor lopinavir/ritonavir 
  concurrently. Because lopinavir/ritonavir increases tenofovir 
blood levels by inhibiting the efflux of tenofovir out of renal 
proximal tubule cells and reduces tenofovir renal clearance, 
the increased tenofovir blood levels during concurrent use 
could have potentially increased fracture risk, in view of 
animal studies linking higher tenofovir concentrations with 
greater demineralization.31,32 In addition, lopinavir/ritonavir 
in the absence of coadministered tenofovir has been linked 
with low bone mineral density and cases of accelerated 
osteoporosis,37 and with vertebral fractures.38 More of our 
tenofovir-treated cohort took oral corticosteroids, were 
chronic cigarette smokers, and had truncal obesity or wasting 
syndrome, all of which have been implicated in reducing bone 
  mineral density.39–42 These factors could have contributed to 
the higher frequency of osteoporosis or osteopenia in the 
tenofovir group, and hence greater likelihood of foot bone 
fragility and fracture. These risk factors were likely partially 
counterbalanced by the greater frequency of use of calcium 
supplements, vitamin D, testosterone, and teriparatide, 
ie, drugs that could increase bone mineral density, in the 
tenofovir group.43–47 It was not clear in some cases when 
these were started with respect to the timing of a diagnosis 
of osteopenia or osteoporosis. Although fewer patients in 
the non-tenofovir group had as many of these bone mineral 
density-reducing factors, more non-tenofovir-treated patients 
were alcoholics or had CD4 counts ,200/mm3, both of which 
can lower bone mineral density.43,46
Our study was limited by its small population and its 
lack of information about the dietary habits and exercise 
patterns of the patients, both of which could have potentially 
impacted bone strength, and hence, foot fracture risk. The 
study involved HIV-infected patients who were diagnosed 
over a one-year period (2006–2007) after having received 
tenofovir on average for about 2.5 years. Thus, they were 
prescribed tenofovir at a time when the nucleoside backbones 
popularly used in practice were lamivudine/zidovudine, 
abacavir/lamivudine, and abacavir/lamivudine/zidovudine. 
It is noteworthy that tenofovir is currently prescribed much 
more often as a backbone in combination HAART regimens. 
Thus, if foot fractures were to be evaluated over the past 
year in HAART-treated patients, the attributability of the 
fracture to tenofovir use could be debatable because more 
fractures might only reflect greater prevalence of tenofovir 
use in current clinical practice. Our study had several 
attributes, including the fact that the patients were well 
matched for severity of HIV condition, family history of 
bone abnormalities, and time between HIV diagnosis and foot 
fracture diagnosis. Most of the patients were not elderly, and 
so the effects of older age on bone fragility were negligible. 
The same data-gathering tool and questions were used in 
evaluating patient medical charts. Lastly, only males were 
evaluated because women have a notably higher frequency 
of low bone mineral density due to smaller body weight and 
hormonal factors.
In conclusion, this small pilot study suggests a greater 
incidence of foot fractures in HIV-infected patients on 
tenofovir-containing than non-tenofovir-containing HAART. 
Comorbidities and/or coadministered drugs may have 
influenced the occurrence of these fractures. When choosing 
antiretroviral agents for inclusion in HAART regimens, 
it is important for clinicians to consider the potential for 
drugs to increase the risk of fracture, especially in HIV-
infected patients in whom bone mineral density is already 






The results of this study were presented in part in poster 
100 at the annual meeting of the American College of 
Clinical Pharmacy, 19–22 October 2008, Louisville, KY; 
and in poster 5 at HIV DART 2006 – Frontiers in Drug 
Development for Antiretroviral Therapies, 9–12 December 
2008, Rio Grande, Puerto Rico. This study was funded by a 
grant from GlaxoSmithKline.
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